Voloridge Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Voloridge Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,972	Closed	-$384K	–	1647
2022 Q1	$384K	Buy	+33,972	New	+$447K	﹤0.01%	1240
2021 Q4	–	Sell	-39,634	Closed	-$679K	–	1869
2021 Q3	$679K	Sell	39,634 -61,468	-61%	-$1.08M	﹤0.01%	1388
2021 Q2	$2.17M	Sell	101,102 -22,619	-18%	-$405K	0.02%	968
2021 Q1	$1.86M	Buy	+123,721	New	+$2M	0.01%	847
2020 Q4	–	Sell	-60,722	Closed	-$587K	–	1590
2020 Q3	$587K	Buy	60,722 +43,939	+262%	+$470K	﹤0.01%	1062
2020 Q2	$192K	Buy	+16,783	New	+$190K	﹤0.01%	1202
2019 Q4	–	Sell	-10,368	Closed	-$138K	–	1363
2019 Q3	$138K	Sell	10,368 -47,425	-82%	-$661K	﹤0.01%	1007
2019 Q2	$814K	Buy	57,793 +8,310	+17%	+$132K	0.02%	492
2019 Q1	$910K	Buy	+49,483	New	+$1.13M	0.03%	507

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management's VNDA Position: Q2 2022 in Review

Voloridge Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 33,972 shares — an estimated $384K sold.

Voloridge Investment Management first reported a position in VNDA in Q1 2019 and held it in 9 quarters. The position peaked at $2.17M in Q2 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

Voloridge Investment Management reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Voloridge Investment Management sold 33,972 Vanda Pharmaceuticals shares in Q2 2022, an estimated $384K.
Voloridge Investment Management first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 9 quarters.
Voloridge Investment Management's Vanda Pharmaceuticals position peaked at $2.17M in Q2 2021.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.